Search PubMed⌕ Search

Biomedical subjects

R Laufs

Publications and source records attributed to R Laufs.

192 records · Page 11Linked to original sources
PubMedDate not supplied

[Imported mussels as a cause of Vibrio parahaemolyticus gastroenteritis].

Two strains of Vibrio parahaemolyticus were isolated from stool specimens of a patient who came down with gastroenteritis 20 hours after eating imported mussels which had not been cooked sufficiently. This is the first documented case of V. parahaemolyticus enteritis acquired in the Federal Republic of Germany.

Adult↗
PubMedDate not supplied

[Infectiousness of a 4-year-old hepatitis B virus carrier and and active immunization of his playmates].

Screening the contacts of a 33-year-old father with acute hepatitis B virus (HBV) infection revealed that this four-year-old adopted son was a persistent HBV carrier with massive viremia. The infection did not occur until they had been in contact for three and a half years. Serological findings from the wife, daughter and one of the children's playmates indicated previous hepatitis B infections which had been healed with a positive immune response. It is highly probable that the son induced these infections. The history of the child with persistent HBV infection as well as the clinical course indicate a perinatally acquired HBV infection. To prevent this infection from spreading further, seven playmates with an average age of five years were actively vaccinated against hepatitis B. The success of this vaccination was compared to a control group of adults. After applying the vaccine three times at four-week intervals, the seroconversion to anti-HBs occurred earlier and the antibody titres were higher in the children. 71% of the children had produced anti-HBs after the first vaccination compared to only 13% of the adults (mean age: 33 years). The rate of seroconversion was 100% for the children after the second vaccination, compared to only 93% for the adults four to six weeks after the third vaccination.

Adult↗
PubMedDate not supplied

Hepatitis C virus antibodies among different groups at risk and patients with suspected non-A, non-B hepatitis.

4000 sera were tested for antibodies against hepatitis C virus (HCV) by means of an ELISA using the C100-3 antigen. 38.9% of patients with non-A, non-B hepatitis following blood transfusion (n = 108) had HCV antibodies. Among patients with chronic liver damage of unknown origin (n = 316) 30.4% were anti-HCV positive, and in 2,506 patients with transitional or chronic elevation of transaminases 14.8% showed HCV antibodies. Haemophiliacs (n = 26) with 65.4% anti-HCV positives and drug addicts (n = 46) with 56.5% anti-HCV positives had the highest prevalence among high risk groups. Addicts dying from drug abuse (n = 216) and HIV 1 positives (n = 127) were anti-HCV positive in 37.5% and 26.0%, respectively. Patients on haemodialysis (n = 331) had antibodies against HCV in 12.4%. Health care workers (n = 217) appear to be at a comparably low risk with only 2.8% anti-HCV positives. Up to now we could not find a single case of intrafamilial spread of HCV in 46 examined cases. We suggest that HCV infectivity of contaminated body fluids and blood is lower than that of hepatitis B virus or human immunodeficiency virus type 1 carriers. In suspected non-A, non-B hepatitis negative test results should be confirmed in a second sample because it may take three to six months after infection before HCV antibodies occur. However, about 10% of chronic HCV infections are not detectable with the presently available test. This may change when new tests become available using HCV specific antigens other than C100-3.

Enzyme-Linked Immunosorbent Assay↗
PubMedDate not supplied

Close correlation between hepatitis C virus serology and polymerase chain reaction in chronically infected patients.

To determine whether the persistent presence of antibodies to recombinant antigens of the hepatitis C virus (HCV) corresponds to the presence of hepatitis C virus RNA in the same serum, 85 anti-HCV positive patients were studied by the polymerase chain reaction (PCR). The focus of the research was on patients with chronic hepatitis. Eighty- three patients were found to be positive by PCR; only two were negative. In addition, liver biopsies taken from seven patients positive for anti-HCV were shown to contain HCV-specific RNA. Sera collected from three patients suspected to have NANB hepatitis on the basis of clinical symptoms were negative both for HCV antibodies and HCV RNA. The correlation between HCV antibody positivity and detection of HCV RNA was 97.6%.

Adult↗
PubMedDate not supplied

Isolation of Chlamydia trachomatis from the lower digestive tract.

Chlamydia trachomatis was isolated from ten of 188 biopsies (5.3%) obtained from different parts of the lower digestive tract. Patients (mean age 37.0 years) presented with ulcerative proctitis, Crohn's disease, mild colitis or ulcerative colitis. Seven rectal biopsies, two biopsies from the sigmoid flexure and one caecal biopsy were positive for chlamydial isolation whereas all biopsies taken from the colon ascendens, transversum or descendens and from the terminal ileum were negative. We conclude that isolation of C. trachomatis is most effective from rectal and sigmoidal biopsies and is a rare event from other sites of the lower digestive tract.

Adult↗
PubMedDate not supplied

In vitro susceptibilities of enterococcal blood culture isolates from the Hamburg area to ten antibiotics.

Treatment of enterococcal infections is often difficult because of intrinsic and acquired resistance to a variety of antimicrobial agents. Between January 1993 and May 1997, enterococci were isolated from blood cultures of 117 patients at the Institute of Medical Microbiology and Immunology, University Hospital Eppendorf, Hamburg, Germany. Eightynine (76%) isolates were phenotypically identified as Enterococcus faecalis, and 24 (21%) as Enterococcus faecium. All E. faecalis isolates, but only 17% of the E. faecium isolates were susceptible to ampicillin. Two E. faecium isolates (8%) but no E. faecalis were vancomycin resistant (vanA genotype). Quinupristin/dalfopristin shows a high degree of susceptiblity of E. faecium (79%) and may be suitable for the therapy of infections caused by glycopeptide-resistant E. faecium strains.

Aged↗
PubMedDate not supplied

Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test.

The in vitro activity of fleroxacin was compared to that of ciprofloxacin, ofloxacin and three broad-spectrum beta-lactams against 159 clinical isolates using the E-Test. Fleroxacin, ciprofloxacin, and ofloxacin were all active against Enterobacteriaceae with 93, 98 and 94% susceptibility, respectively. For other gram-negative strains, 81% were susceptible to fleroxacin and ofloxacin and 98% to ciprofloxacin. With regard to gram-positive strains, 72% were susceptible to fleroxacin, 83% to ciprofloxacin and 78% to ofloxacin. The broad antibacterial activity suggests that fleroxacin may be an alternative in the treatment of various infections, particularly in light of its favorable pharmacokinetics.

Anti-Bacterial Agents↗